Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Shigella4V2 (S4V2) in Prevention of shigellosis. The expected timing is based on the latest available company guidance and may change.
Partnership w/ LimmaTech. 11/13/24- First patient dosed. Conduct a Ph2 pediatric study in Low- and Middle-Income Countries expected to begin before the end of 2024. 4/9/25- First vaccination in Ph2 Infant Study. Topline data in H2 2025. 11/20/25:- Two Ph2 trials ongoing (infant and Ph2b CHIM); further development contingent on positive results. 02/19/26:- First Ph2 S4V2 data to guide program; development decision anticipated in H2 2026. 03/18/26:- Two Ph2 trials ongoing; first Ph2 results expected Mid-2026 with development decision in H2 2026. 05/13/26:- Two Ph2 S4V2 trials ongoing; first Ph2 results still expected Mid-2026; Valneva to assume development if positive. 08/13/26:- Phase 2 infant and Phase 2b CHIM trial results are expected in Q3 2026. Development next steps will follow results.
Verification
Confirm timing and program details against the company announcement or filing.